Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
• By The Pink Sheet
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Avapro (irbesartan), and cancer drug Eloxatin (oxaliplatin)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
